Table 1 Demographics, severity of congenital heart disease (CHD), comorbidities and results of CHA₂DS₂-VASc and HAS-BLED scores

All patients (n)

30

Gender

17 male (57%): 13 female (43%)

Median age

55 years (SD 17 years)

Median duration of therapy (months)

17 (min–max: 3–71)

Total cumulative duration of therapy (months)

764

Complications

Events during therapy

1

Thrombotic or thromboembolic events

0

Bleeding events

1

Severity of CHD

Simple

9

Moderate

11

Complex

8 (27%)

Unclassified

2

Defect repaired

27 (90%)

Bioprosthetic valves

5

Indication for anticoagulation

Non-valvular atrial fibrillation

26

Venous thromboembolism

1

Cerebral embolism

3

Comorbidities

Hypertension

9 (30%)

Diabetes

4 (13%)

Type of novel oral anticoagulants (NOAC)

Apixaban

14

Rivaroxaban

9

Dabigatran

7

Scores

Median CHA₂DS₂-VASc

2 (IQR: 0–3)

0

8

1

4

2

6

3

10

4

1

5

1

Median HAS-BLED

1 (IQR: 0–2)

0

13

1

4

2

12

3

1